Testing a new drug plus pembrolizumab versus pembrolizumab alone
Treatments studied
Part of Cancer, Skin clinical trials.
This Phase 2 trial studies whether adding GB1211 to pembrolizumab works better than pembrolizumab with a placebo in people with metastatic melanoma or metastatic head and neck squamous cell cancer. It may help shrink tumors and improve outcomes, but it also carries risks from immune-based treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have metastatic melanoma (including some rare types) OR metastatic head and neck squamous cell cancer that worsened after platinum chemotherapy
- Your diagnosis has been confirmed on past biopsy or cytology
- You are 18 years or older, and you are well enough for treatment (ECOG 0–2)
- You must have enough time to benefit (expected survival over 12 weeks) and you can sign consent
- If you can become pregnant: you must have a negative pregnancy test within 72 hours before treatment and both partners must avoid pregnancy during the study
- Certain recent treatments and medication timing rules must be met (no cancer therapy in the last 3 weeks, or within 5 blood half-lives)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests pembrolizumab (an immunotherapy medicine) together with induction chemotherapy before the main cancer treatment for stage III/IVA head and neck squamous cell cancer. It aims to improve how well the tumor responds and how long people can stay controlled.
This trial tests whether adding pembrolizumab (an immunotherapy drug) to standard chemotherapy before surgery can help people with advanced head and neck cancer. It aims to see if the combination is more effective than chemotherapy alone.
This trial tests a new drug combination (BL-B01D1 plus a PD-1 inhibitor) for people with advanced head and neck cancer or other solid tumors that have come back or spread. It aims to see if the treatment can help shrink tumors or slow the disease.
This trial tests whether pembrolizumab (an immunotherapy) combined with chemotherapy works better as a first treatment for recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) in the oral/throat area. It aims to improve cancer control and help people live longer with fewer side effects than standard care.
This trial tests a new combination of two immunotherapy drugs (petosemtamab plus pembrolizumab) compared to pembrolizumab alone for people with head and neck cancer that has spread or come back and cannot be cured locally. It may be an option if your cancer has a certain protein (PD-L1) and you haven't had prior cancer treatment for this stage.
This trial tests a combination of immunotherapy (PD-1) and chemotherapy for people with advanced head and neck cancers that are poorly differentiated. The goal is to see if the combination helps shrink tumors before possible surgery or radiation.
Hear when a new Metastatic Melanoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.